Skip to content
InMed-logo-01
  • Pharmaceutical
    • INM-901 for Alzheimer’s Disease
    • INM-089 for Age-related Macular Degeneration
    • INM-755 for Epidermolysis Bullosa
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
  • Pharmaceutical
    • INM-901 for Alzheimer’s Disease
    • INM-089 for Age-related Macular Degeneration
    • INM-755 for Epidermolysis Bullosa
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn

In the Media

  • October 6, 2023

Podcast: Dr. Shane Johnson is guest on The Water Tower Hour (Live Recording from Benzinga Conference)

Dr. Shane Johnson, GM of BayMedica, InMed’s subsidiary, is a guest on The Water Tower Hour podcast. Host Jesse Redmond, Senior Analyst at Water Tower Research interviewed Shane live at the Benzinga Cannabis Capital Conference in Chicago September 28th.

In this interview, Shane talks about InMed and BayMedica’s rare cannabinoid expertise and the synergies between the two companies, the market opportunities for rare cannabinoids, the importance of cannabinoid consistency for consumer products and the challenges of the current cannabinoid landscape.

Shane Johnson enters the podcast at 25:50.

Highlights from Shane’s interview with Jesse:

  • 25:50 – Why attend Benzinga Cannabis Capital Conference? Who’s in attendance?
  • 27:10 – What do InMed and BayMedica specialize in? What are rare cannabinoids?
  • 28:00  – What is THCV? What is THCV used for?
  • 28:50 – What is considered a rare cannabinoid? What other cannabinoids, other than THC and CBD are found in higher quantities in the plant? Does BayMedica commercialize plant-based cannabinoids?
  • 31:15 – How are BayMedica’s and InMed’s businesses differentiated? Do InMed and BayMedica both focus on rare cannabinoids? How do the two businesses complement each other?
  • 33:30 – What are the market opportunities for rare cannabinoids in pharmaceutical and health and wellness. How are they different? What are the challenges for the cannabinoid business?
  • 35:20 – What is driving the recent revenue growth at InMed/BayMedica?
  • 37:20 – What does defined spectrum mean? Why are consumer interested in defined spectrum for their cannabinoid-based products? Why is cannabinoid consistency such an important quality in consumer products?
  • 40:00 – What are the biggest challenges facing the cannabinoid industry?
  • 44:20 – What is the 2024 outlook for BayMedica?

Podcast available on multiple platforms

Apple: https://podcasts.apple.com/us/podcast/the-water-tower-hour/id1693448305?i=1000630167209…
Google: https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5idXp6c3Byb3V0LmNvbS8yMTc2NDc2LnJzcw/episode/QnV6enNwcm91dC0xMzcxMjg3MQ?sa=X&ved=0CAUQkfYCahcKEwigu8KixNyBAxUAAAAAHQAAAAAQAQ…
Spotify: https://open.spotify.com/show/65HhA2UPZVDW55kA3sCkXh…

Full Article
Source: The Water Tower Hour

Share this post

Latest Articles

InMed Presents at Renmark Financial Virtual Non-Deal Roadshow

InMed’s President and CEO, Eric A. Adams, presents at Renmark Financial’s Virtual Non-Deal Roadshow on February 26, 2026. In the presentation and Q&A, Mr. Adams

Read More
March 10, 2026

InMed’s CEO Eric A. Adams Gives An Overview of Alzheimer’s Disease Drug Candidate INM-901

How is INM-901 different from other Alzheimer’s therapeutics? What is INM-901’s mechanism of action? How does INM-901 work? Is INM-901 expected to be orally available?

Read More
February 23, 2026

Conference Presentation – InMed Presents at Life Sciences Forum December 11, 2025

In this update on InMed Pharmaceuticals, CEO Eric A. Adams talks about the company’s Alzheimer’s disease program. Mr. Adams talks about the role of inflammation

Read More
January 12, 2026
InMed-logo-mono

#1445 – 885 West Georgia St.
Vancouver, BC, Canada
V6C 3E8

Pharmaceutical

  • INM-901 for Alzheimer’s Disease
  • INM-089 for Age-related Macular Degeneration
  • INM-755 for Epidermolysis Bullosa

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM Materials
  • Filings
  • Presentations
  • Media & Videos
  • Investor Contact

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisors
  • Partners and Collaborators
  • Careers
  • Contact

Learn

  • Articles and Videos
  • Webinar: Alzheimer’s Outlook – Neuroinflammation, the Next Step
  • The Evolving Alzheimer’s Disease Landscape

© Copyright 2026 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*
Consent*